Share on StockTwits

Spectranetics Corp. (NASDAQ:SPNC) CFO Guy Childs sold 5,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $24.90, for a total value of $124,500.00. Following the completion of the transaction, the chief financial officer now directly owns 138,945 shares of the company’s stock, valued at approximately $3,459,731. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Spectranetics Corp. (NASDAQ:SPNC) traded down 1.16% on Thursday, hitting $24.71. The stock had a trading volume of 256,188 shares. Spectranetics Corp. has a 52 week low of $14.58 and a 52 week high of $25.60. The stock’s 50-day moving average is $23.35 and its 200-day moving average is $19.34. The company’s market cap is $1.012 billion.

Spectranetics Corp. (NASDAQ:SPNC) last released its earnings data on Thursday, October 24th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $39.76 million for the quarter, compared to the consensus estimate of $38.97 million. During the same quarter in the prior year, the company posted $0.04 earnings per share. The company’s quarterly revenue was up 12.9% on a year-over-year basis.

SPNC has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Spectranetics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Monday. They now have a $27.20 price target on the stock. Separately, analysts at CRT Capital initiated coverage on shares of Spectranetics Corp. in a research note to investors on Monday, November 25th. They set a “buy” rating and a $26.50 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Spectranetics Corp. from $26.00 to $30.00 in a research note to investors on Friday, October 25th. They now have a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $24.53.

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.